Strategy

Nightingale Health’s blood analysis technology can be utilized by healthcare providers, insurance companies, governments and health systems, companies offering consumer health services, telehealth providers, as well as universities and research institutions conducting medical research.

Based on the blood analysis technology developed by Nightingale Health, the company offers its customers chronic disease risk assessments, and a broad panel of blood values commonly used in healthcare. Nightingale Health’s technology detects the risks of the most common chronic diseases from a single blood sample wider and with less effort and without compromising detection accuracy compared to existing clinical risk assessment tools. This capability is unique in the market and plays a key role in addressing the most pressing challenge in modern healthcare: chronic diseases in an aging population.

The disease risk assessments currently made in healthcare consume so much healthcare resources that they cannot be utilized for assessing disease risks at the population level. The health check developed by Nightingale Health is by far the most efficient and effective solution for large-scale risk detection. The health check detects the risks associated with various common chronic diseases from a single blood sample. Because the health check requires only one blood sample, it can be used to broadly assess disease risks at the population level without using the already scarce healthcare resources. This is why Nightingale Health’s health check can both replace many of the current routine tests and risk assessments in healthcare and enable systematic risk assessment for everyone. Systematic risk assessment allows for measuring the impact of the interventions of healthcare providers and directing efforts and funding towards the operating models that have the greatest impact on reducing disease risks.

It is of utmost importance to tackle the health and cost challenges related to chronic diseases. Preventative healthcare is not possible without means for effective, holistic and cost-efficient risk detection. The health check based on Nightingale Health’s blood analysis technology is the key to building a preventive healthcare system. The better we understand future disease risks, the better we can target preventive measures and reduce the number of sick people in the future.

Win new large international deals

Nightingale Health aims to win new international flagship deals and convert pilots to commercial contracts to accelerate the adoption of Nightingale Health’s technology in large-scale healthcare use

• KPI: Win a large-scale international healthcare project

Increase revenue

Nightingale Health aims to continue increasing its revenue, despite the fact that new deals typically take more than 12 months to ramp-up and convert into revenue

• KPI: Increase revenue compared to previous financial year

Improve efficiency

Nightingale Health will continue investing in growth while preserving the strong cash position and solid runway

• KPI: Improve adjusted EBITDA* level compared to previous financial year
  

*Adjusted EBITDA = EBITDA – share-based payments – extraordinary items – items affecting comparability

• To conclude an agreement to analyze two million samples annually in Europe
• To conclude an agreement to analyze ten million samples annually in the United States or in Asia
• To extend laboratory capacity in respective geographical areas to meet the analysis capacity required by the aforementioned agreements
• To achieve positive EBITDA

• To analyze 100 million blood samples from partnerships with the healthcare sector, health initiatives, and white label partners
• To generate EUR 500 million in annual revenue from partnerships with the healthcare sector, health initiatives, and white label partners